Wed, Jul 23, 2014, 9:51 PM EDT - U.S. Markets closed

Recent

% | $
Click the to save as a favorite.

EnteroMedics Inc. Message Board

  • aenadeona aenadeona Feb 9, 2013 8:39 PM Flag

    THE STUDY WASNT GOOD BUT THEY PLAN ON MOVING WITH APLLICATION TO FDA ???? THATS WEIRD

    EnteroMedics Inc. ( ETRM ) slumped over 49% in extended trading Thursday after the company announced that its phase III trial evaluating VBLOC vagal blocking therapy for the treatment of obesity failed to meet predefined efficacy endpoints.

    However, the trial, dubbed ReCharge, did demonstrate a clinically meaningful and statistically significant excess weight loss of 24.4% for VBLOC Therapy-treated patients, with 52.5% of patients achieving at least 20% excess weight loss, noted the company.

    Based on the available data, EnteroMedics plans to move forward with a Pre-Market Approval application with the FDA in the second quarter of 2013.

 
ETRM
1.55-0.02(-1.27%)Jul 23 4:00 PMEDT

Trending Tickers

i
Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.
Facebook, Inc.
NasdaqGSWed, Jul 23, 2014 4:00 PM EDT
Gilead Sciences Inc.
NasdaqGSWed, Jul 23, 2014 3:59 PM EDT